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Introduction
Pain is a sensory response that normally helps the body to respond to a source of danger or tissue damage and facilitates protection for tissue repair. Acute pain arises from a range of noxious stimuli including heat, cold, mechanical stimuli, and chemicals. In the case of burninduced pain, damage to peripheral sensory neurons and inflammatory processes initiated by the injury exacerbate this acute response and transform burn pain into a complex symptom comprising multiple components, including ongoing background pain and procedural pain during surgical interventions and dressing changes. In addition, burn-induced pain can persist beyond the initial injury and develop into chronic pain with neuropathic features.
Typically, the degree of pain is largely determined by how deep the burn penetrates, with areas of superficial burns resulting in greater pain than areas of fullthickness burns, where the nerve endings are functionally compromised or lost. However, fullthickness burns are typically surrounded by areas of more superficial injury, so that, clinically, patients with full-thickness burns report as much pain as those with a superficial injury [1] . The duration of pain can last from days to months.
The skin, the largest organ of the human body by weight, plays many essential roles, including maintaining body homeostasis, providing an immunological barrier, and contributing to sensations of touch and pain. The skin consists of two primary layers ( Figure 1 ): the outer epidermis, which is predominantly made up of keratinocytes plus melanocytes, Merkel cells, and Langerhans cells; and an inner dermis, comprising connective tissue, fibroblasts, macrophages, and adipocytes. The skin is intensely innervated with many morphologically and functionally distinct sensory nerve endings that respond to a multitude of non-noxious and noxious stimuli. Noxious heat stimuli are generally conducted to the dorsal horn of the spinal cord via nociceptive Ad and C fiber neurons.
The classification of a burn injury is dependent both on the depth and area of the burn. The depth of burn injuries was first classified by Peter Lowe in 1597 and modified by Fabricius in 1610 to the terms "first-, second-, and third-degree burns." This remained largely unchanged until recently, when a new system described burn injuries as either epidermal, superficial epidermal, mid-dermal, deep dermal, and full thickness [2] . The burn coverage, also called the total body surface area (TBSA), provides an estimate of the percentage of the skin burnt [3] and is determined according to the "Rule of Nines." The TBSA, together with burn depth, the presence of inhalation burn, age, and gender, is used to calculate the severity of a burn injury using scales such as the Abbreviated Burn Severity Index (Table 1 ) [4] that provide an estimate of prognosis for the patients and the method of treatment.
The aim of this review is to provide an overview of burn injury epidemiology, current treatments for burn injury, and the mediators and mechanisms underlying burn injury pain. We conducted a systematic evaluation of the literature regarding the epidemiology of burn pain, discuss the advantages and limitations of various models of burn injury, summarize key burn injury pain mechanisms, and provide an overview of common approaches to treating burn pain.
Methods

Epidemiology of Burn Injuries
A systematic search was performed on Medline (October [18] [19] 2016 ) to retrieve studies related to the following search key word combinations: burn; burns; epidemiology; mortality; gender; age. Articles published between January 2000 and October 2016 in English were then selected from the list, along with selected references informing the results of the retrieved studies. Articles were classified according the level of evidence, as detailed in Table 2 . Searches for national registries for burn injury were also included in the study. Articles were excluded if they focused on a particular Figure 1 The severity of a burn injury is determined by the depth of tissue injury. The skin is intensely innervated with many morphologically and functionally distinct sensory nerve endings that respond to a multitude of non-noxious and noxious stimuli. Noxious heat stimuli are generally conducted to the dorsal horn of the spinal cord via nociceptive Ad and C fiber neurons. Only the epidermis is affected in epidermal or superficial epidermal burns while increasing damage to the dermis occurs in mid-dermal, deep-dermal and full-thickness burns.
Burn Pain demographic or subsection of a population, if the study contained fewer than 100 patients, or if a higher level of evidence was available. . Only randomized controlled studies assessing the efficacy of a pharmacological intervention in comparison with placebo or other analgesic(s) with a primary outcome measure of pain in hospitalized burn patients were included. The titles, abstracts, and the full texts of these articles were screened for relevance. Studies assessing nonpharmacological interventions were excluded. Studies assessing topical and wound care interventions that were aimed only at improving the healing process were excluded.
Treatment of Acute Burn Pain
Results and Discussion
Epidemiology of Burn Injuries
A number of epidemiology studies have been undertaken to try to capture the current state of burn injury prevalence in different regions. These studies include national burn and trauma registries, multicenter and single-center studies, systematic reviews, and questionnaires. In this systematic review, we aimed to capture the current best evidence for burn injury prevalence around the world, provide a critical analysis of the quality of the evidence, and describe where and how data capture needs to improve.
In total, 163 publications of interest were obtained, and of those 63 fit the exclusion and inclusion criteria. Three burn injury registries were identified; one from the United States, another from Australia and New Zealand, and a third from England and Wales. These registries Systematic review or multicenter study Level 3 Single-center study Level 4 Self-reporting and their epidemiological reports (annual or cumulative) added an additional nine references, totaling 72 references. A burn registry in Iran that is not accessible online was identified through publications along with studies (eight in total) using data from national trauma registries, and these were considered level 1 evidence. The majority of studies (41) obtained were of level 3 evidence involving single-center studies. This level of evidence was deemed less reliable as comparisons between level 3 evidence studies within the same country often produced variability in measures (Table 3) .
Burn victims are usually men, with only seven of the 72 studies reporting greater female representation than male ( Table 3 ). The vast majority of burns occur in the home (73% USA; 76% Australia and New Zealand; 65.89% England and Wales), and the most common source of injury is flame and scald exposure (Table 3) , but injuries were also from contact burns, radiation, chemicals, and electricity (Table 4) , with these being accidental, inflicted, or self-inflicted. No age group is immune from this traumatic experience, but there is a significant occurrence of burn injuries, predominantly from scalds, in children age five years and younger (Table 4) and for adults between 20 and 29 years. In Europe, burn injuries affect between two and 29 people per 100,000, with males representing 60% of cases [5] , while in the United States males represent approximately 70% of all burn cases in the age group of 20 to 60 years (Table 5 ) [6] . In comparison, 3.98% (four people per 100) of those in Sierra Leone self-reported burn injuries, although the extent of these injuries was not specified [7] . Burns can lead to morbidity through wounds and inflammation, scarring, infection, amputations or surgical resections, psychological conditions, and ongoing pruritis and acute and chronic pain.
Mortality varied throughout the world, with studies reporting between less than 1% and up to 60.8%. The mortality rate correlated with the Human Development Index (HDI) (Figure 2A ), with developing countries more likely to report higher mortality than developed countries. Mortality also correlated with the total burn surface area, with greater surface area resulting in a higher likelihood of death ( Figure 2 , B and C). In highly developed countries, burn injuries commonly affect less than 10% of the total body surface area (84% Australia and New Zealand; 96.5% England and Wales; 77.9% USA); however, in countries with lower HDI scores, a greater TBSA was often reported presenting to hospitals (Table  3 ). The mortality of clinically presenting cases is reported as between 0.8% and 1.2% in Australia and New Zealand, between 1.4% and 18% in Europe [5] , and 3.14% in the United States [8] . Mortality resulting from burn injury was higher in females than males in England and Wales (1.86% vs 1.31%, respectively) [9] and Australia and New Zealand (2.32 times more likely to succumb to injury compared with males, adjusted for confounding factors) [10] .
In total, the publications examined in this systematic review covered 58 countries with HDI scores ranging from 0.465 to 0.944, along with regional studies from South Asia and Europe. It is problematic that few countries with lower HDI scores have high-quality (level 1 and 2) evidence as burn injury disproportionately affects those in developing countries. Globally, more than 11 million people experience burn injury requiring medical attention annually, with the majority of severe burn cases affecting people in emerging economies, including an estimated 50% of cases in Southeast Asia [11] . The World Health Organization is currently testing a Global Burn Registry, which allows for standardization of data collection and will provide greater access to epidemiological data from developing countries. A systematic review found a decrease in burn injury prevalence and injury severity in very high and highly developed countries over time, but with data under-reported for low-and middle-income countries, where the majority of burn injuries occur, no conclusions could be made on trends there [12] . Databases for burn injury statistics established in highly developed countries provide high-quality data to draw conclusions on clinical outcomes and burn injury trends, but these registries have limitations also. While the International Burn Injury Database (England and Wales) provides data describing whether pain scores have been taken from patients, measures of pain outcomes are omitted from all repository annual reports. Epidemiological data for pain scores included in burn injury repositories could provide ongoing measures describing how adequately burn injury is managed and where improvements can be made.
Animal Models of Burn Injury Pain
Animal models have provided some important insights into human pain associated with burn injury. There is a limited number of randomized placebo-controlled clinical trials available to evaluate the effectiveness of analgesics in human burn patients (discussed in detail below), in part because burn patients are a heterogeneous group with variable levels of burn severity and background demographics and are frequently quite unwell, with multi-organ dysfunction. While a number of human volunteer studies of burn pain have been reported-including models of dry heat contact burn, ultraviolet (UV) burn, and capsaicin-induced heat sensitization-these are for obvious reasons not numerous [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] . Although all of these models have demonstrated the development of secondary hyperalgesia, likely due to central sensitization, such models are unlikely to address the need for ongoing research into the pathophysiological mechanisms underlying burn pain. Given the importance of this area to improving patient outcomes, a number of animal models have been established specifically to study the mechanisms of burn pain (Table 6 ). However, it is unclear how predictive animal models of burn-induced pain are of the human condition as many other animal models of pain in the past have failed to translate to the clinic [97] . Nevertheless, improvements in experimental design and efficacy end points are likely to increase the clinical validity of animal models of pain in the future.
Animal models of burn-induced pain are typically based on a burn injury that is induced on the plantar skin of one hind paw in rodents, in contrast to animal models used to study other aspects of burn injury, such as wound healing, metabolic changes, and infection, where a larger burn injury is commonly induced on the dorsum or ventral skin of mice, rats, or pigs [119, 120] . The advantage of using the plantar skin of the hind paw is that it readily allows the quantification of pain behaviors, including changes in mechanical and thermal thresholds or weight-bearing behaviors in the ipsilateral hind paw.
Dry Contact Heat
Dry contact heat is the most commonly used method for inducing burn injury in rodents and involves exposing the plantar skin of one hind paw to a heated-often metal-surface while the rodents are under anesthesia. This is a clinically relevant model as contact with a dry heat source such as an iron, vehicle exhaust, or heater accounts for 9-14% of burns cases [8, 16] . To induce a mild burn injury or superficial burn in rats, the metal surface is set to a temperature of 52-52.5 C and the skin is exposed for 45 seconds, with constant pressure maintained by applying a sand pouch with a set weight to the dorsal surface of the hind paw. This model leads to the rapid development of mechanical and thermal allodynia in the injured hind paw, evident within 30 minutes of burn injury and persisting for at least seven days [104, 98, 106] . This protocol has also been modified for use in mice by reducing the exposure time to 25 seconds [121] . In the mouse model, mechanical and thermal allodynia develop rapidly and persist for at least four days, along with changes in weight-bearing behavior. The main advantage of mouse models of burn injury pain is in the ability to study the specific effects of gene deletion on the development of burn pain in knockout mice.
To induce a partial-thickness injury (with blistering) in rats, the contact surface is set to a temperature of 85 C and the skin is exposed for 15 seconds. This model leads to the rapid development of mechanical allodynia in the injured paw that persists for eight weeks; however, unlike the mild burn injury model, little to no thermal allodynia is observed [110] . The above protocol used in rats can be slightly modified to produce a partial-thickness injury model in mice, using a temperature of 65 C and exposing the plantar surface of one hind paw for 15 seconds [113] . This model leads to the rapid development of mechanical and thermal allodynia that will persist for seven to 14 days. 
Scalding
Scalding is a method where burn injuries are induced by immersing the dorsum or ventral skin of mice or rats in water (60-100 C) to induce burns of varying degree, dependent on the time and temperature of exposure, and is commonly used to study other aspects of burn injury as opposed to the pain-related behavior [119] . However, modified scald methods that produce burn injury on the hind paws of rats have been described [114, 116] . This model is relevant to the clinic as scalding is responsible for a third of burns requiring hospitalization [8, 16] . Immersing only the dorsal surface of the hind paw in water at 85 C for 12 seconds induces a third-degree burn injury, resulting in mechanical and thermal allodynia on the plantar surface of the hind paw of rats that lasts for at least seven days, albeit this method is associated with significant tissue damage and thus raises ethical concerns [116] .
Soldering
This recently described method utilizes a soldering iron to apply a 100 C heat stimulus for 30 seconds to the plantar surface of the hind paw to induce a burn injury in rats [117, 118] . This model results in a full-thickness burn injury that takes four weeks to resolve. Mechanical and thermal allodynia is not present at the actual site of the burn injury, consistent with local destruction of cutaneous nerve endings, but can be detected in the adjacent skin for two weeks after burn injury [118] . Although no changes in thermal hyperalgesia or mechanical allodynia were detected in the contralateral paw, expression of both calcitonin gene-related peptide (CGRP) and Substance P was upregulated in the contralateral dorsal horn, suggesting changes consistent with central sensitization. This method is associated with significant tissue damage that necessitates wound management and antibiotic treatment and may thus lead to ethical concerns that would be justified predominantly for studies aiming to determine effects on wound healing and systemic impact of burn injuries. However, this method may be suitable to model burn injury induced by direct contact with a flame, the most common cause of burn injury in the clinic [8, 16] .
Ultraviolet Radiation
The UV method involves exposure of the plantar surface of the hind paw of rats to ultraviolet B radiation to induce a burn injury. A dose of 1,000 mJ/cm 2 causes a superficial burn injury without blistering, along with mechanical and thermal allodynia that develops rapidly and persists for seven days [122, 123] . While UV radiation can be dosed more precisely than scalding or dry heat contact, it is unclear whether the mechanisms underlying a burn injury induced by UV radiation are similar to other causes of thermal injury. It is clear that UV radiation is associated with DNA damage, and in humans the long-term effects of UV burns include development of skin cancers. Surprisingly, thermal burns are associated with a significant increase in cancer burden, possibly due to systemic inflammatory processes [124, 125] . Averaged percentages from three studies [5, 8, 82] , with results shown for infants (0-12 mo), children (1-15 y), adults (16 y), pediatric (0-16 y), and elderly (60 y). It thus remains to be determined whether exposure to UV radiation is a suitable model for assessing mechanisms underlying burn-induced pain more generally.
Clinical Applicability of Animal Models
Researchers have an ethical obligation to refine approaches in studies involving animals to minimize the pain, suffering, and distress as much as possible. Therefore, in the case of animal models of burn pain, careful consideration must be given to determine the severity of burn injury and study duration necessary to achieve experimental outcomes. As such, most animal models of burn-induced pain reported in the literature are of mild severity (equivalent to a superficial or partial-thickness burn) and of short duration (days to weeks). It is unclear if the severity of the burn has an impact on the underlying mechanisms of pain, and thus whether these milder pain models serve as appropriate models for more severe burns typically necessitating clinical intervention. In addition, the duration of these animal studies is typically relatively short, thereby modeling acute pain as opposed to chronic pain, which, as described below, is clinically more difficult to manage and can continue for months to years despite healing.
The animal models described thus far tend to focus on stimulus-evoked rather than background pain as they apply mechanical or thermal stimuli to the injured area and quantify withdrawal responses. It could be argued that stimulus-evoked pain is a surrogate measure of procedural pain, which, as described below, can often be severe and difficult to manage. Quantifying background pain in animals can be challenging, although behavioral methods that quantify non-stimulus-evoked pain are increasingly being developed [126] [127] [128] . Finally, the majority of animal models of burn pain induce a burn injury on glabrous or nonhairy skin, which in humans is located on palms of the hands and soles of the feet. The sensory innervations between hairy and nonhairy skin differ [129, 130] , and it is unclear what impact this has on the translation to pain from burns that occur on hairy skin.
Burn Injury Pain Mechanisms
Both human and animal studies have provided significant insight into the mechanisms underlying pain after a burn injury, which has a complex pathology with both peripheral (Figure 3 ) and central processes [131, 132] and combines features of acute nociceptive, inflammatory, and neuropathic pain. However, the significant diversity in the causes and severity of burn injuries make it difficult to determine the relative contribution of different pathways in individual cases. It should thus be noted that, in the context of this review, it is not currently possible to attribute the relative importance of those mechanisms to the individual pain experience or analgesia.
Peripheral Nociceptive Mechanisms and Adaptations in Burn Injuries
Acute Burn Injury Pain. The threshold temperature for formation of edema in the skin in response to heat is 43 C, which is also the threshold temperature for activation of the transient receptor potential vanilloid type 1 ion channel (TRPV1) [133, 134] . Accordingly, TRPV1 activation has been functionally linked to the development of thermal allodynia in partial-thickness burns [112] . Oxidized linoleic acid generated by thermal injuries also acts as an agonist at TRPV1 and activates the receptors post-burn injury [112] . Stimuli above 52 C result in activation of TRPV2 [135] , while TRPV3 and TRPV4 are Figure 2 Mortality was found to be correlated with the (A) human development index score (HDI; R 2 ¼ 0.335) and (B and C) total burn surface area (R 2 ¼ 0.616 and 0.752, respectively). TBSA ¼ total body surface area.
Table 6
Animal models of burn-induced pain Activation of the thermosensitive channels causes the release of calcitonin gene-related peptide (CGRP) from the primary sensory nerves, which in turn results in the elevation of intracellular Ca 2þ levels. The deteriorating cell membrane releases ATP, which targets P2X receptors on primary sensory nerves. The voltage-gated sodium channel (Na V ) 1.7 is essential for thermal allodynia. The trauma caused to the cell membranes will result in the release of damage-associated molecular pattern molecules (DAMPs) that will bind to Toll-like receptors, P2X receptors and AIM2-like receptors (ALRs). Following this trigger histamine, catecholamines, TNF-a, IL-1b, IL-6, oxygen free radicals, nitric oxide (NO), bradykinin, and arachidonic acid cascade products are released. Furthermore, leukocytes, eicosanoids (including prostaglandins [PGs]), and platelet-activating factors (PAFs) are recruited. PGE2 activates prostanoid EP1-4 on mast cells, and subsequently histamine is released. Prostanoid EP3-4, located on the primary afferent terminals and mast cells, furthermore results in release of IL-6. Lastly, a catecholamine 5-hydroxytryptamine (5-HT) is also released at the site of injury and sensitizes the peripheral nerves by acting at 5-HT2A. thermosensitive channels that are gated by innocuous temperatures above 33 C and 25 C, respectively. However, while thermal injury-induced keratinocyte death has been at least partially attributed to TRPV1-TRPV4 isoforms, the contribution of these thermosensitive channels, specifically TRPV2-TRPV4, to burninduced pain has to-date not been systematically assessed [136] . Similarly, the transient receptor melastatin 3 ion channel (TRPM3), which is activated at relatively low temperatures, has also been shown to play a role in heat nociception, with TRPM3-deficient mice displaying attenuated avoidance of noxious heat stimuli [137] . Activation of these thermosensitive channels has been shown to evoke the release of the neuropeptide CGRP from the terminals of primary sensory nerves, and, accordingly, elevated circulating CGRP levels have been found shortly after burn injury [138] . In addition, the neuropeptide Substance P has been found to be significantly higher in the blood of patients within 12 hours of suffering a burn injury [138] . CGRP acts directly on a subset of dorsal root ganglion (DRG) neurons, causing elevated intracellular Ca 2þ and enhancing tetrodotoxin (TTX)-resistant sodium current density in cultured sensory neurons [139] . Substance P also has direct effects on nociceptors, with lumbar DRGs superfused with Substance P displaying a prolonged depolarization [140] . Levels of both Substance P and CGRP in different layers of the skin have been correlated to the sensation of pain during wound healing and scarring in burn patients [141] , suggesting that they play a role in the maintenance of pain after the initial heat insult.
The loss of cell membrane integrity due to elevated heat results in the release of cell contents, some of which have also been shown to directly activate nociceptive neurons. Specifically, ATP is released from the deteriorating cell membrane, with the ATP metabolite adenosine found in the fluid of burn blisters [142] . The pharmacological targets of ATP are the P2X receptors on primary sensory fibers, where both P2X2 and P2X3 are thought to play a role in burn injury pain. The P2X3 receptor in particular is upregulated in peripheral nerve terminals of rats after burn injury, and P2X3 antagonists also inhibited P2X-activated currents in isolated DRGs from the same animals [143] . In addition, the release of protons from the acidified inflamed environment likely further enhances the effect of ATP on P2X2 receptors, resulting in enhanced perception of pain [144] .
The voltage-gated sodium channels (Na V ) play select roles in burn injury pain. The Na V blocker TTX was effective at reducing thermal hyperalgesia and mechanical allodynia after full-thickness burn injury in rats [117] , suggesting that TTX-resistant isoforms, specifically the sensory neuron-specific Na V 1.8 and Na V 1.9, play a limited role in burn pain. Consistent with this observation, the TTX-sensitive isoform Na V 1.7 was essential for thermal allodynia in a mouse model of a partial-thickness burn injury, albeit mechanical allodynia was unaffected in Na V 1.7 knockout mice. In addition, burn injury resulted in reduced threshold of TTX-sensitive DRGs from wild-type mice but not from Na V 1.7 knockout mice, suggesting that Na V 1.7 is essential for thermal hypersensitivity after burn injury [113] . These observations are consistent with the clinical phenotype of humans with a congenital mutation resulting in loss of function of Na V 1.7, who frequently present with painless burn injuries [145] . Given the intense drug discovery efforts directed at identifying subtype-selective Na V 1.7 inhibitors, it appears likely that novel analgesics with efficacy in acute burn pain will be developed in the future.
Inflammatory Burn Injury Pain. A burn results in an acute inflammatory response that can be restricted to the site of injury or involve systemic inflammatory processes that trigger a syndrome associated with significant morbidity and mortality. Trauma from a severe burn injury results in denaturing of proteins and the leakage of cell plasma due to the loss of cell membrane integrity. A necrotic trauma like this results in the release of damageassociated molecular pattern molecules (DAMPs) [146] from the cell plasma, which subsequently bind to various inflammatory receptors including Toll-like receptors [147] [148] [149] , P2X receptors, and AIM2-like receptors (ALRs) [150] , among others. Activation of DAMP receptors and localized ischemia/reperfusion events result in activation of the alternative complement pathway [151], the release of histamine [152] , catecholamines, TNF-a, IL-1b, IL-6 [153] , oxygen free radicals, nitric oxide, bradykinin, and arachidonic acid cascade products, as well as the activation and recruitment of leukocytes. Histamine release results in early local vascular leakage and peripheral edema, while reperfusion events result in localized cell apoptosis [154] . Accordingly, activation of peripheral sensory nerve terminals after burn injuries as well as sustained nociceptive input post-injury occurs through a range of stimuli, including the initial thermal insult, vascular damage, hypoxia from ischemic events, DAMP receptor activation, and local release of proinflammatory and algogenic mediators and transmitters such as bradykinin, histamine, eicosanoids, plateletactivating factor (PAF), nerve growth factor (NGF), Substance P, and CGRP.
Bradykinin, an important mediator of peripheral vascular permeability and pain, has been implicated in burn injury pain since a bradykinin-like substance was found in the urine of patients with burn injuries [155] . In addition, intradermal administration of the selective bradykinin 2 receptor antagonist, HOE-140, reduced the occurrence of edema in a model of burn injury [156] and reduced mechanical allodynia in a model of sterile inflammatory pain [157, 158] .
Similarly, histamine was detected in the urine of burn patients [157] and in blister fluid, with levels correlating to edema formation [152] . Burn injury pruritus or itch is also mediated by histamine, with 70% of patients reporting effective relief with antihistamines [159] .
A number of eicosanoids have been identified both at the site of burn injury and systemically, including prostaglandins (PG) E2, PGF1a, PGF2a, thromboxane B 2 [160] , and leukotrienes [161] , and these are believed to contribute to burn pathology. PGE2 is a particularly important inflammatory mediator in burn pain and contributes to hyperalgesia in a number of ways. These include activation of the prostanoid receptors EP1-4, which causes the release of histamine from mast cells [162] , activation of prostanoid EP3 and EP4 receptors on primary afferent terminals and mast cells, causing the release of IL-6 [162, 163] , sensitization of the activation threshold of TTX-resistant Na V channels [164] , inhibition of voltage-gated potassium currents [164] , and sensitization of TRPV1 through prostanoid EP1 receptors [165] . Accordingly, nonsteroidal anti-inflammatory drugs (NSAIDs) are a firstline treatment for burn pain and are discussed further in the Treatments section.
Cytokines and inflammatory mediators released both locally and from recruited leukocytes mediate inflammation and wound healing, but also contribute to burn-induced allodynia and hyperalgesia. The cytokine and immune modulators IL-1b, IL-6, IL-8, TNF-a, and TGFb, as well as platelet-derived growth factor, have all been found in the blister fluid of burn patients [153] . While IL-1b has been shown to be an important mediator of burn-induced inflammation, knockout of caspase-1, an enzyme that cleaves IL-1b into its active form, had no effect on burn-induced mechanical or thermal allodynia in mice [166] . IL-6, on the other hand, has been shown to be an important mediator of burn injury pain [146] . In rats subjected to a partial-thickness burn, IL-6 concentrations were elevated at the site of the burn correlating with the duration of pain, and treatment with intradermal anti-IL-6 antibodies significantly reduced pain [167] . In addition, subcutaneous administration of IL-1b, IL-8, and TNF-a result in mechanical and thermal hyperalgesia, suggesting that it is likely that these cytokines contribute to burn injury hyperalgesia [168] [169] [170] .
PAF has been isolated from polymorphonuclear leukocytes of burn injury patients [171] , and administration of exogenous PAF results in hyperalgesia [172] . PAF receptor-deficient mice display normal thermal and mechanical allodynia but show decreased persistent pain in response to tissue injury, suggesting that PAF plays a role in sensitizing peripheral sensory nerves [173] . Similarly, in animal models of peripheral nerve injury, intrathecal administration of PAF receptor antagonists decreased mechanical and thermal allodynia mediated by the glycine receptor 3a [174] . Thus, while the contribution of PAF to burn-induced pain has not been systematically assessed, modulation of this inflammatory mediator may prove a viable option for treatment of inflammatory pain associated with burn injury.
Given the substantial body of literature describing the role of NGF in pain, it is not surprising that this important growth factor has also been ascribed a specific contribution to burn-induced pain. NGF is released into regenerating skin [175] and contributes to the development of systemic hyperalgesia as administration of anti-NGF serum resulted in the inhibition of hyperalgesia in burn injury [176] . NGF-induced systemic hyperalgesia is mediated by a reduced expression of lumbar l-opioid receptor expression and increased activation of glutamate receptors. Accordingly, administration of MK-801, an NMDA receptor antagonist, inhibited systemic hyperalgesia after thoracic burn injury, consistent with upregulation of NMDA receptor transcripts in DRG neurons from mice following burn inury [107, 177] . It appears that the high-affinity receptor for NGF, tropomyosin receptor kinase (TrkA), likely mediates these hyperalgesic effects as intrathecal administration of antisense oligodeoxynucleotides to TrkA resulted in dose-related decrease of burn-induced primary mechanical hyperalgesia. Thus, anti-NGF treatment may provide substantial benefits to burn patients, albeit this remains to be assessed clinically [104] .
The catecholamine 5-hydroxytryptamine (5-HT) is also released at the site of burn injury and found systemically [178] . Administration of exogenous 5-HT results in nociceptive behavior including mechanical and thermal hyperalgesia and allodynia [179] [180] [181] , which is mediated by the 5-HT 1A , 5-HT 2A , and 5-HT 3 receptors [180] [181] [182] . In an animal model of mild plantar thermal injury, a selective 5-HT 2A receptor antagonist resulted in a reduction in mechanical and thermal allodynia when administered at the site of injury [183] , demonstrating that locally released 5-HT sensitizes peripheral nerves by acting at 5-HT 2A [183] .
Activation of peripheral adrenoceptors is known to result in the production of cytokines and in nerve regeneration. In the subsequent weeks after a full-thickness burn, the expression of the a1-adrenoreceptor is increased in peripheral nerve terminals and in keratinocytes at the site of injury [184] , albeit changes in expression of a1-adrenoreceptor subtypes were not systematically assessed. While administration of the selective a1-adrenoceptor agonist phenylephrine resulted in increased hyperalgesia in a human study of mild burn that could be inhibited by a selective a1-adrenoceptor antagonist, analgesia after administration of selective a1-adrenoceptor antagonists alone has not yet been shown [185] .
Neuropathic Burn Injury Pain. By definition, neuropathic pain occurs as a result of lesions or disease of the somatosensory nervous system [186] . While the contribution of neuropathic components to burn pain is not routinely considered, perhaps due to the parallel experience of other forms of pain, it is not surprising that patients can develop both acute and chronic neuropathic pain given the extensive damage to the somatosensory system in burn injury. Burn-induced damage to cutaneous nociceptors and their superficial conducting fibers likely gives rise to ectopic firing and other pathological processes that cause features of acute and chronic neuropathic pain, which are often described as "burning pain," "on fire," "pins and needles," and "stabbing" sensations [187] . These descriptors, combined with the underlying mechanism of injury, may indicate that the patient is suffering from a form of acute neuropathic pain [188] . Indeed, this pain could very appropriately be referred to as "phantom skin pain"-a phrase first coined by Atchison and colleagues in 1991 [1] .
While the mechanisms underlying burn-induced neuropathic pain have not been studied in detail, treatments including gabapentin and pregabalin are reportedly effective in some patients with neuropathic pain symptoms [189, 190] , suggesting that the pathophysiology of burn-associated neuropathic pain resembles that of other types of neuropathic pain, at least to some degree.
Central Nociceptive Mechanism and Neuronal Adaptations to Burn Pain
Central sensitization appears to be a key contributor to burn-induced pain. Chronic, bilateral hyperexcitability of wide dynamic range neurons and microglial activation in the spinal cord accompany burn injuries [109] . Reversal of these changes by treatment with minocycline, a tetracycline antibiotic that inhibits microglial activation and prevents neuropathic pain in other models with central components, was paralleled by a decrease in burninduced allodynia, lending further support to the importance of central mechanisms.
Early spinal sensitization is thought to develop through the activation of the NMDA glutamate receptor and subsequent calcium influx as intrathecal administration of MK-801 has been shown to block both behavioral and electrophysiological measures of spinal sensitization [191, 192] . In addition, the development of secondary hyperalgesia seen in burn injury is prevented by intrathecal administration of AMPA receptor antagonists [103] , suggesting that enhanced glutamatergic signaling plays a key role in central sensitization after burn injury [193] .
In addition, due to systemic activation of DAMP receptors and the direct effects of C5a, TNF-a, IL-1b, matrix metalloproteinases, and other pro-inflammatory mediators, the blood-brain barrier becomes compromised after burn injury. DAMP receptor activation within the brain results in cerebral inflammation characterized by increased levels of pro-inflammatory cytokines (IL-1b, IL-6, and TNF-a) in the brain and cerebral edema. Central inflammation can be seen as a result of a scalding burn. This can lead to states of delirium and dizziness. The upregulation of IL-1b within the brain activates cyclooxygenase and the subsequent production of prostaglandins, and this has been shown to contribute to centrally mediated hyperalgesia [194] . TNF-a in the brain contributes to the development of neuropathic pain [195] .
Moreover, based on pathophysiological similarities to other types of pain, a contribution of descending inhibitory pathways to modulation of burn pain could be expected, although this has not been systematically investigated.
Treatment of Acute Burn Pain
Acute pain occurs immediately following burn injury and can continue for several months until wound healing is complete as patients undergo many return trips to the operating theater, repeated dressing changes and baths, and regular sessions of rehabilitation that include stretching and physiotherapy. Acute burn pain has a complex pathology with central and peripheral processes, consisting of three dominant pain types: background pain, procedural pain, and neuropathic pain. Effective treatment of each of these pain types, which will be discussed further below, requires the prescription of regular multimodal analgesia with the addition of carefully titrated breakthrough analgesia accompanied by frequent review and assessment by experienced health professionals. Treatment is generally based on local burn center guidelines as limited randomized placebo-controlled clinical trials are available to evaluate the effectiveness of analgesics specifically in the burns population.
A number of techniques have been described to assess the level of pain experienced due to a burn injury, which should take into account the intensity of the pain as well as behavioral and physiological responses. In general, adult patients are asked to describe their pain using a numeric pain scale (0-10), visual analog scale (transected line), or verbal scale (no pain to worst pain) [196, 197] . Assessing the severity of pain in small children and infants is more complex, with face scales (e.g., Wong-Baker Faces Pain Rating Scale) and behavioral observations by medical staff being a more common measure [198] .
Our search strategy yielded a total of 213 articles describing treatment of burn pain, of which only 14 articles fitted our inclusion/exclusion criteria (Table 7) , highlighting the limited availability of randomized placebocontrolled clinical trials to assess analgesic efficacy in the burns population. Most studies (11/14) focused on the treatment of procedural pain; two studies focused on background pain, and one study focused on neuropathic pain. Although topical interventions are likely to have an impact on burn pain, studies assessing pharmacological treatments alone are difficult to carry out as wound care interventions, such as dressing changes and debridement, form the standard of care for partialand full-thickness burns.
Background Pain
Background pain is a continuous nociceptive inflammatory pain that is present while the patient is at rest. Pain management strategies that apply to other forms of pain Burn Pain Table 7 Randomized double-blind clinical trials for the treatment of burn pain also apply to burn injury pain-that is, the utilization of well-directed, carefully titrated, and regularly reviewed multimodal analgesia to cover a myriad of receptors and pain pathophysiologies. This typically includes regular acetaminophen (paracetamol), regular NSAIDs where appropriate, and the use of long-acting opioid preparations, with specific recommendations varying between burns centers [212] .
The use of ketamine in the burn-injured patient is largely reserved for the facilitation of procedures such as dressing changes, which will be discussed in the next section. A constant ketamine infusion to assist with background pain management is utilized in some burns centers. In addition to assisting with analgesia, ketamine is thought to produce benefits through effects on the NMDA receptor, which may reduce central sensitization, as discussed above. However, the psychomimetic effects of ketamine may be distressing for some patients, which limits its use [213] .
Procedural Pain
An especially distressing aspect of burn care for patients is procedural pain from interventions including physiotherapy, baths, and dressing changes. Due to the constraints of hospital services, many of these interventions are done on the ward rather than in the operating theater under general anesthesia. The pain during these interventions naturally reaches quite intense levels for a brief period of time and is often difficult to manage. Options to manage procedural pain include combinations of short-acting opioids, benzodiazepines, and subanesthetic doses of nitrous oxide/oxygen or ketamine. Short-acting parenteral or immediate-release opioids, such as morphine, oxycodone, or fentanyl, can be used for procedural pain. These can be given in addition to the sustained-release oral or transdermal opioids that are providing assistance with the constant background pain. The choice of opioid, dose, and route of administration depend on the patient and type of procedure being performed. Although they are effective analgesics, opioids have many dose-limiting adverse effects, including sedation, respiratory depression, nausea, vomiting, and constipation. Depending on the duration of treatment, dose escalation may also be required as tolerance to the analgesic effects of opioids develops over time. However, the risk of opioid-induced hyperalgesia must always be considered if there is escalating use of opioids in the presence of poorly controlled pain. This effect may also be seen acutely when higher doses of remifentanil are used intraoperatively with subsequent hyperalgesia and difficult-to-control pain during the recovery phase after surgery. Polymorphisms in the l-opioid receptor may also result in variable responses to opioid analgesics [214] .
Although not considered analgesic, benzodiazepines can be effective in alleviating pain symptoms in combination with other analgesics, most likely due to their sedative and anxiolytic effects [215] . This has been demonstrated in a randomized, placebo-controlled trial in burn patients, which found lorazepam to be effective in reducing pain scores compared with placebo when administered in combination with opioid analgesics [216] . Benzodiazepines with a short to moderate duration of action, such as midazolam and lorazepam, are preferred to longer-acting drugs.
Nitrous oxide is an inhalant anesthetic that has modest analgesic properties when delivered at subanesthetic doses [216] . Inhaled nitrous oxide and oxygen mixtures can be a very effective form of analgesia for short procedures, such as dressing changes [202] , as it has a rapid onset (within seconds) and short duration of action. Although it is generally well tolerated, nitrous oxide can cause nausea and vomiting, precluding its use in some patients. Repeated or prolonged administration of nitrous oxide can interfere with vitamin B12 metabolism, causing serious hematological and neurological adverse effects and necessitating monitoring and vitamin B12 supplementation as required [217] .
Ketamine is an intravenous anesthetic that can have potent analgesic effects when administered at subanesthetic doses. For the management of procedural pain, ketamine is generally administered by the intravenous or intramuscular route, with a fast onset of action (1-5 minutes) and relatively short duration of action (10-30 minutes) [218] . Ketamine induces a dissociative state, where patients appear awake but are nonresponsive, and requires close monitoring by an experienced health professional for potential adverse effects, including airway obstruction due to hypersalivation and transient respiratory depression [219] . Upon recovery, patients can experience distressing psychomimetic symptoms, including delirium, agitation, and hallucinations. The incidence of psychomimetic effects is much lower in children compared with adults and can be reduced by co-administration with a benzodiazepine [218] . Despite these adverse effects, ketamine has been demonstrated to provide effective analgesia for procedural pain in both adult and pediatric burn patients [201, 209, 210] . Some burns centers use an intravenous patient-controlled sedation device where patients can provide their own sedation using a solution containing ketamine and midazolam [220] .
Regional anesthesia, where a large part of the body, such as an arm or leg, is anesthetized, can also be used. This can include using a fascia iliaca block to provide anesthesia to the antero-lateral thigh, a common site used to acquire donor skin, or a brachial plexus block, which provides anesthesia for procedures involving the arm. On occasion, patients may require a major procedure, which for various reasons cannot be performed in the operating theater under general anesthesia. Therefore, a deeper level of analgesia and sedation, using a combination of the above analgesic/ anesthetics may be required on the burns ward.
Staff appropriately trained with skills in pharmacotherapy and airway management are required to perform this task.
In addition to pharmacological interventions, the power of nonpharmacological approaches cannot be underestimated. Hypnosis with post-hypnotic suggestion and virtual reality, a technologically advanced method of distraction where patients are actively engaged in another task while undergoing procedural interventions, are emerging as important nonpharmacologic options with strong evidence and support [221, 222] .
Neuropathic Pain
Many of the signs and symptoms in patients with burn injuries resemble features that are often present in those with neuropathic pain, which is not surprising given extensive damage to cutaneous nociceptors and conducting nerve fibers following burn injury. This neuropathic pain can occur acutely, being present only at the time of burn injury, and may become chronic despite healing of the burn injury. As is generally the case with burninduced pain, limited randomized placebo-controlled trials assessing the effectiveness of treatments for neuropathic pain in the burn population are available. Systematic reviews have concluded that gabapentin and pregabalin are effective in the treatment of other neuropathic pain states, such as diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia [223, 224] , and their use in burn pain has therefore been investigated. Gabapentin was shown to be ineffective in the treatment of acute burn pain compared with placebo in a small randomized trial; however, this result could be explained by a large proportion (70%) of patients without neuropathic pain being included in the study [200] .
In contrast, pregabalin was demonstrated to be effective in alleviating acute neuropathic symptoms following burn injury in a study that only included patients with neuropathic pain symptoms [189] . Use of systemic lignocaine has also been investigated, although no conclusions can be drawn about effectiveness in burn injury based on current evidence [225] . While one study found a statistically significant reduction in pain scores following intravenous administration of lignocaine, the pain score reduction (-0.4 on a 10-point pain scale) was unlikely to be clinically relevant [203] . The use of tricyclic antidepressants and other anticonvulsants that are usually used to treat neuropathic pain has not been systematically investigated in the burn population, although they are used in some burn centers.
Treatment of Chronic Pain Following Burn Injury
Chronic pain following healing of a burn injury can have a debilitating impact on the function and quality of life of patients, and finding effective management remains a significant challenge. The incidence of chronic pain following burn injury is reported to be between 25% and 36%, and it is correlated with the severity of the initial burn injury [226] [227] [228] . To date, there is no evidence that any one intervention is able to reduce the incidence of chronic pain in the burn-injured population. However, this lack of evidence does not negate the absolute need for effective multimodal analgesia in the acute period following the injury and the requirement for this therapy to be reviewed and titrated on a regular basis. General principles of chronic pain management should be employed and should include multimodal analgesia in the setting of a supportive interdisciplinary team with psychological intervention as required. The use of longterm opioid therapy for the management of chronic pain following burn injury should, as for all forms of chronic noncancer pain, be diligently monitored for ongoing benefit and adverse outcomes.
Conclusions
A burn injury is one of the most severe forms of trauma that a person may experience and is associated with significant pain and numerous physical, psychological, material, and social losses. The impact of a burn injury on the patient is a result of a multitude of factors and complex processes that together drive the experience of pain. First and foremost, the physical damage to the skin not only determines the acute nociceptive response, but also contributes to the transition to chronic pain states. Pain after a burn encompasses nociceptive, inflammatory, and neuropathic components and may persist well beyond healing of the injury, with central sensitization being a key contributor to ongoing pain. The complex pathophysiological mechanisms underlying burn pain contribute in part to the difficulties in effective clinical management, but also present significant opportunities for synergistic analgesic approaches, albeit mechanism-based treatments specific to burn pain are not widely used clinically as yet. Current treatment selection is driven by patient symptoms and is based on analgesics that are efficacious for other pain types with similar symptoms, with the assumption that the underlying mechanisms are comparable.
Given the high incidence of burn injuries and the significant morbidity associated even with minor burns, improved pain management is essential to improve the quality of life of burn patients. However, relatively few human clinical studies have been reported as burn patients typically belong to a very heterogeneous population and frequently present with significant comorbidities. Accordingly, animal models of burn pain have provided considerable insight into the underlying mechanisms of pain from burn injuries and may contribute to the development of novel analgesic strategies. With a better characterization of the underlying mechanisms that drive burn pain, improved mechanism-based treatments promise to deliver analgesia with fewer side effects and ultimately improve quality of life for these patients. amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate receptors mediate development, but not maintenance, of secondary allodynia evoked by first-degree burn in the rat. J Pharmacol Exp Ther 2004;310(1):223-9.
